

Supplementary information pertaining to

Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of Acute Myeloid Leukemia

Lorenza Destro,^a Valentina Crippa,^b Daniela Gabbia,^c Marco Roverso,^d Sara Bogialli,^d Paolo Zardi,^a Giovanni Marzaro,^e Luca Mologni,^b Alfonso Zambon^{a*}

a Department of Chemical and Geological Sciences, University of Modena and Reggio Emilia, Modena, Italy

b Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

c Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo, Italy.




d Department of Chemistry, University of Padova, via Marzolo 1, Italy.

e Department of Diagnostic and Public Health, University of Verona, Piazzale Antonio Scuro 10, Verona, Italy

Table of Contents

Substructure search conducted on different pyrazolyl- urea scaffolds	3
MD simulations of compound 10q on WFLT3	4
Metabolite ID data for compounds 10c , 10q	5
Synthetic Procedures for all compounds	7
NMR Spectra of final compounds	44

Table S1. Substructure search conducted on different pyrazolyl- urea scaffolds in Scifinder[®] (Chemical Abstracts Services) – accessed November 2024

Search input			
Substructures	3510	442	19
Journal Articles	433	33	5
Patents	3077	409	14




Figure S1. Summary of molecular dynamics simulation with WT-FLT3. A) Calpha-RMSD; B) **10q** heavy atoms RMSD; C) number of hydrogen bonds between FLT3 and **10q**; D) distance between **10q** carbonyl oxygen and amide nitrogen of Cys694 (hinge region of FLT3); E) distance between the center of benzene ring of **10q** and the center of benzene ring of Phe830 (DFG motif); F) distance between the center of benzene ring of **10q** and the center of benzene ring of Phe691. The dashed red lines set at 0.5 nm in panel E-F indicate the common distance for a T-shaped arene-arene interaction




Figure S2: Panel A: Extracted Ion Chromatograms (EIC) for compound, m/z 419.2442; Panel B: EIC for m/z 421.2598 (hydrogenation) obtained after treating compound **10c** with human liver microsomes for 30 min (the treatment with mouse microsomes produced **10c** comparable results). Panel C: MS/MS spectrum acquired in HCD mode with a normalized collision energy (NCE) of 35 for compound **10c** and proposed structures for fragments; Panel D: MS/MS spectrum acquired in HCD mode with a normalized collision energy (NCE) of 35 for the species at m/z 421.2598 (rt 10.97 minutes) and proposed structures for fragments.





Figure S3: Panel A: Extracted Ion Chromatograms (EIC) for compound **10q**, m/z 391.2129; Panel B: EIC for m/z 393.2286 (hydrogenation) obtained after treating compound **10q** for 30 min with human liver microsomes (the treatment with mouse microsomes produced comparable results). Panel C: MS/MS spectrum acquired in HCD mode with a normalized collision energy (NCE) of 35 for compound **10q** and proposed structures for fragments; Panel D: MS/MS spectrum acquired in HCD mode with a normalized collision energy (NCE) of 35 for the species at m/z 393.2286 (rt 10.97 minutes) and proposed structures for fragments

Synthetic Procedures

General procedure A

Starting materials nitrile **1a-c** (4 mmol) and hydrazine **2a-c** (4.24 mmol) were dissolved under Argon atmosphere to a dried Schlenk flask in dry toluene (2 mL); when hydrochloride **1b** was used -1 additional eq. of Et₃N (4.24 mmol) was also added. The reaction mixture was stirred at 116 °C for 72h. The solvent was removed under vacuum and the crude purified by column chromatography as detailed.

3-(tert-butyl)-1-phenyl-1H-pyrazol-5-amine **3a**




Following general procedure A compound **3a** was obtained starting from **1a** and **2a**. **4a-3a** was purified by column chromatography (Silica, petroleum ether:EtOAc 7:3, R_f = 0.33). Concentration in vacuo of the product-rich fractions gave **3a** as a light orange solid (758 mg; yield 88%).

¹H-NMR (600 MHz, Chloroform-*d*) δ (ppm): 1.31 (s, 9H, (CH₃)₃), 5.52 (s, 1H, pyrazole), 7.27 – 7.32 (m, 1H, aromatic), 7.40 – 7.47 (m, 2H, aromatic), 7.54 – 7.57 (m, 2H, aromatic).

¹³C-NMR (151 MHz, Chloroform-*d*) δ (ppm): 30.66, 60.75, 88.01, 124.36, 127.29, 129.73, 139.18, 145.12, 162.69.

ESI-MS (m/z): theoretical 216.15 [C₁₃H₁₇N₃+H]⁺, experimental 216.27 [C₁₃H₁₇N₃+H]⁺.

3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-amine **3b**




Following general procedure A compound **3b** was obtained starting from **1a** and **2b**. **4d-3b** was purified by column chromatography (Silica, petroleum ether:EtOAc 7:3, R_f = 0.31). Concentration in vacuo of the product-rich fractions gave **4d-3b** as light orange solid (522 mg; yield 72%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.17 (s, 9H, (CH₃)₃), 1.36 (d, 6H, (CH₃)₂CH), 3.30 (s broad, 2H, NH₂), 4.24 (hept, 1H, CH(CH₃)₂), 5.32 (s, 1H, pyrazole).

¹³C-NMR (151 MHz, Chloroform-*d*) δ (ppm): 21.95, 30.61, 31.05, 48.66, 88.44, 91.61, 142.91, 159.84, 207.13.

ESI-MS (m/z): theoretical 182.16 [C₁₀H₁₉N₃+H]⁺, experimental 182.26 [C₁₀H₁₉N₃+H]⁺.

3-(tert-butyl)-1-methyl-1H-pyrazol-5-amine **3c**




Following general procedure A compound **3c** was obtained starting from **1a** and **2c**. **3c** was purified by column chromatography (Silica, petroleum ether:EtOAc 7:3 → 0:1, R_f = 0.31). Concentration in vacuo of the product-rich fractions gave **4c-3c** as pale-yellow solid (429 mg; yield 70%).

¹H-NMR (600 MHz, Chloroform-*d*) δ (ppm): 1.29 (s, 9H, (CH₃)₃), 2.15 (s, 2H, NH₂), 3.72 (s, 3H, NCH₃), 5.45 (s, 1H, pyrazole).

¹³C-NMR (151 MHz, Chloroform-*d*) δ (ppm): 27.81, 30.57, 30.63, 34.29, 35.70, 88.64, 146.07, 160.65.

ESI-MS (m/z): theoretical 154.13 [C₈H₁₅N₃+H]⁺, experimental 154.29 [C₈H₁₅N₃+H]⁺.

3-isopropyl-1-phenyl-1H-pyrazol-5-amine **3d**




Following general procedure A compound **3d** was obtained starting from **1b** and **3a2a**. **4b-3d** was purified by column chromatography (Silica, petroleum ether:EtOAc 7:3, R_f = 0.28). Concentration in vacuo of the product-rich fractions gave **4b-3d** as light orange solid (764 mg; yield 95%).

¹H-NMR (600 MHz, Chloroform-*d*) δ (ppm): 1.23 (d, *J* = 7.0 Hz, 6H, (CH₃)₂CH), 2.88 (hept, *J* = 7.0 Hz, 1H, CH(CH₃)₂), 3.83 (s broad, 2H, NH₂), 5.35 (s, 1H, pyrazole), 7.18 – 7.50 (m, 5H, aromatic).

¹³C-NMR (101 MHz, Chloroform-*d*) δ (ppm): 22.86, 28.27, 87.84, 124.09, 127.21, 129.53, 138.66, 145.22, 159.91.

ESI-MS (*m/z*): theoretical 202.14 [C₁₂H₁₅N₃+H]⁺, experimental 202.24 [C₁₂H₁₅N₃+H]⁺.

1,3-diisopropyl-1H-pyrazol-5-amine **3e**




Following general procedure A compound **3e** was obtained starting from **1b** and **2b**. **3e** was purified by column chromatography (Silica, petroleum ether:EtOAc 7:3, *R_f* = 0.21). Concentration in vacuo of the product-rich fractions gave **3e** as pale-yellow solid (468 mg; yield 70%).

¹H-NMR (400 MHz, Chloroform-*d*) δ (ppm): 1.17 (d, *J* = 6.9 Hz, 6H, (CH₃)₂CH), 1.41 (d, *J* = 6.7 Hz, 6H, (CH₃)₂CHN), 2.85 (hept, *J* = 6.9, 1.8 Hz, 1H, CH(CH₃)₂), 3.44 (s, 3H, NH₂), 4.26 (hept, *J* = 6.7, 1.9 Hz, 1H, NCH(CH₃)₂), 5.34 (s, 1H, pyrazole).

¹³C-NMR (151 MHz, Chloroform-*d*) δ (ppm): 22.01, 22.46, 23.26, 28.31, 48.33, 88.21, 143.50, 157.85.

ESI-MS (*m/z*): theoretical 168.15 [C₉H₁₇N₃+H]⁺, experimental 168.09 [C₉H₁₇N₃+H]⁺.

3-isopropyl-1-methyl-1H-pyrazol-5-amine **3f**




Following general procedure A compound **4h-3f** was obtained starting from **2b-1b** and **3e-2c**. **4h-3f** was purified by column chromatography (Silica, petroleum ether:EtOAc 7:3 → 0:1, *R_f* = 0.38). Concentration in vacuo of the product-rich fractions gave **4h-3f** as pale-yellow solid (390 mg; yield 70%).

¹H-NMR (600 MHz, Chloroform-*d*) δ (ppm): 1.22 (d, *J* = 6.9 Hz, 6H, (CH₃)₂CH), 2.74 – 2.94 (hept, *J* = 7.0 Hz, 1H, CH(CH₃)₂), 3.65 (s, 3H, CH₃), 5.40 (s, 1H, pyrazole).

¹³C-NMR (151 MHz, Chloroform-*d*) δ (ppm): 23.08, 28.28, 34.27, 88.58, 145.51, 158.13.

ESI-MS (m/z): theoretical 140.11 [C₇H₁₃N₃+H]⁺, experimental 140.26 [C₇H₁₃N₃+H]⁺.

3-cyclopropyl-1-phenyl-1H-pyrazol-5-amine **3g**




Following general procedure A compound **3g** was obtained starting from **1c** and **2a**. **3g** was purified by column chromatography (Silica, petroleum ether:EtOAc 7:3, R_f = 0.32). Concentration in vacuo of the product-rich fractions gave **3g** as light orange solid (542 mg; yield 68%).

¹H-NMR (600 MHz, Chloroform-*d*) δ (ppm): 0.80 (d, *J* = 5.0 Hz, 2H, CH₂), 0.99 (d, *J* = 8.3 Hz, 2H, CH₂), 1.83 – 2.17 (m, 1H, CH), 4.02 (s, 2H, NH₂), 5.32 (d, *J* = 1.2 Hz, 1H, pyrazole), 7.35 – 7.40 (m, 1H, aromatic), 7.49 (t, *J* = 7.5 Hz, 2H, aromatic), 7.53 – 7.57 (m, 2H, aromatic).

¹³C-NMR (151 MHz, Chloroform-*d*) δ (ppm): 8.90 (d, *J* = 8.4 Hz), 9.82, 123.77, 127.70, 129.90 (d, *J* = 2.4 Hz), 156.29, 8.39, 9.39, 87.16, 124.65, 124.91, 130.07.

ESI-MS (m/z): theoretical 200.11 [C₁₂H₁₃N₃+H]⁺, experimental 200.20 [C₁₂H₁₃N₃+H]⁺.

3-cyclopropyl-1-isopropyl-1H-pyrazol-5-amine **3h**



Following general procedure A compound **3h** was obtained starting from **1c** and **1b**. **3h** was purified by column chromatography (Silica, petroleum ether:EtOAc 7:3, R_f = 0.16). Concentration in vacuo of the product-rich fractions gave **3h** as light orange solid (436 mg; yield 66%).

¹H-NMR (600 MHz, Chloroform-*d*) δ (ppm): 0.55 – 0.64 (m, 2H, CH₂), 0.79 – 0.90 (m, 2H, CH₂), 1.44 (d, *J* = 6.7 Hz, 6H, (CH₃)₂CH), 1.88 (tt, *J* = 5.0, 8.4 Hz, 1H, CH(CH₂)₂), 4.27 (hept, *J* = 6.7 Hz, 1H, CH(CH₃)₂), 5.11 (s, 1H, pyrazole).


¹³C-NMR (151 MHz, Chloroform-*d*) δ (ppm): 8.23, 9.95, 22.25, 48.46, 87.13, 144.03, 154.13.

ESI-MS (m/z): theoretical 166.12 [C₉H₁₅N₃+H]⁺, experimental 166.28 [C₉H₁₅N₃+H]⁺.

General procedure B

Pyrazoles **3a-f** (0.72 mmol where not otherwise stated) and bromophenyl isocyanates **4a-g** (0.88 mmol where not otherwise stated) were added to a dried Schlenk flask under Argon atmosphere and dissolved in anhydrous DCM (4 mL). The reaction mixture was stirred overnight, after which the volatiles were removed in vacuo. The resulting crude was macerated overnight in diethyl ether (20 mL), after which the suspension was filtered and dried in vacuo to afford bromo urea **3a-x**.

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-phenylurea **5a**




Following general procedure A compound **5a** was obtained from **3a** (60 mg, 0.24 mmol) and phenyl isocyanate **4a** (33 mg, 0.28 mmol). Yield: 18 mg, 22%;

¹H-NMR (600 MHz, DMSO) δ 9.00 (1 H, s, NH), 8.39 (1 H, s, NH), 7.54-7.53 (4 H, m, Ph), 7.42-7.40 (3 H, m, Ph), 7.28-7.25 (2 H, t, J=7.6 Hz, Ph), 6.99-6.96 (1 H, t, J=7.4 Hz, Ph), 6.38 (1 H, s, Pyrazole), 1.29 (9 H, s, tBu);

¹³C-NMR (150 MHz, DMSO) δ 161.2, 152.0, 139.0, 137.7, 129.8, 129.3, 127.7, 124.8, 122.6, 118.6, 95.9, 32.5, 30

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3-chlorophenyl) urea **5b**




Following general procedure A compound **5b** was obtained from **3b** (35.4 mg, 1.64 mmol) and 2-chlorophenyl isocyanate **4b** (24 mg, 1.52 mmol). Yield 465 mg, 82 %;

¹H-NMR (600 MHz, CDCl₃) δ 7.36-7.32 (5 H, m, Ph), 7.26-7.23 (1 H, t, Ph-Cl), 7.11-7.08 (1 H, d, Ph-Cl, J=8.21 Hz), 7.07-7.04 (1 H, d, J=8.21 Hz, Ph-Cl), 6.98-6.96 (1 H, d, J=8.16 Hz, Ph-Cl), 6.33 (1 H, s, Pyrazole), 1.29 (9 H, s, *t*Bu);

¹³C-NMR (150 MHz, CDCl₃) δ 162.7, 151.6, 138.9, 134.7, 130.0, 129.6, 128.4, 124.8, 124.0, 119.9, 117.9, 97.0, 32.5, 30.2

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3,5-dimethylphenyl) urea **5c**




Following general procedure A compound **5c** was obtained from **3a** (168 mg, 0.78 mmol) and 3,5-dimethylphenyl isocyanate **4c** (313 mg, 2.13 mmol). Yield 13.1 mg, 14 %;

¹H-NMR (600 MHz, CDCl₃) δ 7.37-7.31 (4H, m, Ph), 7.26-7.23 (1H, t, J=7.2 Hz, Ph), 6.85 (1H, s, 3,5-CH₃Ph), 6.80 (2H, s, 3,5-CH₃Ph), 6.67 (2H, s, NH), 6.36 (1H, s, Pyrazole), 2.17 (6H, s, CH₃), 1.29 (9H, s, *t*Bu);

¹³C-NMR (150 MHz, CDCl₃) δ 162.5, 151.9, 139.1, 137.1, 129.6, 128.2, 126.5, 126.1, 124.8, 119.1, 118.9, 96.3, 32.5, 30.2, 21.3

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3-(trifluoromethyl) phenyl) urea **5d**




Following general procedure A compound **5d** was obtained from **3a** (359 mg, 1.58 mmol) and 3-trifluoromethylphenyl isocyanate **4d** (273 mg, 1.46 mmol). Yield 206 mg, 36 %;

¹H-NMR (600 MHz, CDCl₃) δ 9.02 (2 H, s, NH); 7.59 (1 H, s, CF₃-Ph); 7.37 (1 H, d, J=7.9 Hz, CF₃-Ph), 7.25-7.22 (5 H, m, Ph), 7.08-7.05 (2 H, m, CF₃-Ph), 6.94 (1 H, s, Pyrazole), 1.37 (9 H, s, *t*Bu);

¹³C-NMR (150 MHz, CDCl₃) δ 160.9, 155.8, 150.0, 139.3, 138.5, 130.3, 129.6, 129.4, 128.6, 126.4, 123.0, 122.9, 122.3, 120.7, 94.7, 32.6, 29.2

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-isopropylurea **5e**




Following general procedure A compound **5e** was obtained from **3a** (99 mg, 0.46 mmol) and isopropyl isocyanate **4g** (126 mg, 1.48 mmol). The mixture was purified by flash column silica chromatography. Ethyl acetate and petroleum ether (1:3 – 1:1 – 3:1) were used as the eluent to give the title compound as a pale brown solid Yield 25.2 mg, 18 %;

¹H-NMR (600 MHz, CDCl₃) δ 7.50-7.45 (4 H, m, Ph); 7.36-7.34 (1H, t, J=7.25, 1.5, Ph); 6.22 (1 H, s, Pyrazole); 3.98-3.90 (1 H, septet, CH, J=6.6 Hz, 7.4 Hz) 1.35 (9 H, s, *t*Bu); 1.11-1.09 (6 H, d, J=6.5 Hz, CH₃);

¹³C-NMR (150 MHz, CDCl₃) δ 162.5, 153.7, 138.3, 136.0, 129.5, 127.8, 124.3, 97.5, 42.6, 32.5, 30.3, 23.0

1-(4-bromophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea **5f**




Following general procedure B compound **5f** was obtained from **3a** and isocyanate **4e** as a white solid (179 mg; yield 60%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.28 (s, 9H, (CH₃)₃), 6.37 (s, 1H), 7.44 – 7.35 (m, 5H, aromatic), 7.52 (d, J = 5.1 Hz, 4H, aromatic), 8.43 (s, 1H, urea), 9.15 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 32.05, 95.79, 113.49, 120.08, 124.26, 127.27, 129.29, 131.55, 136.98, 138.56, 138.84, 151.57, 160.79.

ESI-MS (m/z): theoretical 413.09 [C₂₀H₂₁BrN₄O+H]⁺, experimental 413.28 [C₂₀H₂₁BrN₄O+H]⁺.

1-(3-bromophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea **5g**




Following general procedure B compound **5g** was obtained starting from **3a** and isocyanate **4f**. After filtration **5g** was still impure. Therefore, the resultant residue was purified by chromatographic columns (Silica, DCM:EtOAc 98:2, $R_f = 0.18$). **5g** was obtained as a white solid (134 mg; yield 45%).

$^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ (ppm): 1.28 (s, 9H, $(\text{CH}_3)_3\text{C}$), 6.38 (s, 1H, pyrazole), 7.15 (m, 1H, aromatic), 7.25 – 7.18 (m, 2H, aromatic), 7.41 (m, 1H, aromatic), 7.52 (m, 4H, aromatic), 7.83 (s, 1H, aromatic), 8.48 (s, 1H, urea), 9.21 (s, 1H, urea).

$^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ (ppm): 87.04, 96.05, 112.76, 115.91, 117.04, 117.85, 120.44, 121.79, 122.50, 124.30, 124.71, 127.36, 129.02, 129.36, 130.78 (d, $J = 8.5$ Hz), 136.90, 138.58, 141.13, 151.66, 160.88.

ESI-MS (m/z): theoretical 413.09 $[\text{C}_{20}\text{H}_{21}\text{BrN}_4\text{O}+\text{H}]^+$, experimental 413.59 $[\text{C}_{20}\text{H}_{21}\text{BrN}_4\text{O}+\text{H}]^+$.

1-(4-bromophenyl)-3-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)urea **5h**




Following general procedure B compound **5h** was obtained starting from **3a** and isocyanate **4e** as white solid (137 mg; yield 50%).

$^1\text{H-NMR}$ (400 MHz, DMSO- d_6) δ (ppm): 1.21 (s, 9H, $(\text{CH}_3)_3$), 1.33 (d, $J = 6.6$ Hz, 6H, $(\text{CH}_3)_2\text{CH}$), 4.34 (hept, $J = 6.7$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 6.00 (s, 1H, pyrazole), 7.35 – 7.50 (m, 4H, aromatic), 8.36 (s, 1H, urea), 8.99 (s, 1H, urea).

$^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ (ppm): 22.25, 30.50, 31.98, 45.85, 47.80, 54.95, 94.84, 113.48, 115.85, 120.23, 120.35, 131.61, 135.19, 139.00, 139.06, 152.28, 158.59.

ESI-MS (m/z): theoretical 379.11 $[\text{C}_{17}\text{H}_{23}\text{BrN}_4\text{O}+\text{H}]^+$, experimental 379.54 $[\text{C}_{17}\text{H}_{23}\text{BrN}_4\text{O}+\text{H}]^+$.

1-(3-bromophenyl)-3-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)urea **5i**




Following general procedure B compound **5i** was obtained starting from **3b** and isocyanate **4f** as white solid (251 mg; yield 92%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): δ 1.22 (s, 9H, (CH₃)₃), 1.34 (d, *J* = 6.6 Hz 6H, (CH₃)₂CH), 4.34 (hept, *J* = 6.6 Hz, 1H, CH(CH₃)₂), 6.01 (s, 1H, pyrazole), 7.15 (m, 1H, aromatic), 7.23 (t, *J* = 8.0 Hz, 1H, aromatic), 7.30 (m, 1H, aromatic), 7.85 (t, *J* = 2.0, 1H, aromatic), 8.43 (s, 1H, urea), 9.07 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 22.19, 30.56 (d, *J* = 39.4 Hz), 47.70, 94.79, 117.02, 120.41, 121.70, 124.49, 130.71, 135.04, 141.30, 152.18, 158.48, 206.49.

ESI-MS (*m/z*): theoretical 379.11 [C₁₇H₂₃BrN₄O+H]⁺, experimental 379.76 [C₁₇H₂₃BrN₄O+H]⁺.

1-(4-bromophenyl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea **5k**




Following general procedure B compound **5k** was obtained starting from **3d** and isocyanate **4e** as a white solid (195 mg; yield 68%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.23 (d, *J* = 6.9 Hz, 6H, (CH₃)₂CH), 2.89 (hept, *J* = 6.9 Hz, 1H, CH(CH₃)₂), 6.32 (s, 1H, pyrazole), 7.35 – 7.46 (m, 5H, aromatic), 7.52 (d, *J* = 4.4 Hz, 3H, aromatic), 8.46 (s, 1H, urea), 9.14 (s, 1H, urea).

¹³C-NMR (151 MHz, Chloroform-*d*) δ (ppm): 159.68, 151.46, 136.85, 132.01, 129.73, 128.97, 124.99, 121.32, 116.57, 29.72, 27.88, 22.42, 1.03.

ESI-MS (*m/z*): theoretical 399.08 [C₁₉H₁₉BrN₄O+H]⁺, experimental 399.46 [C₁₉H₁₉BrN₄O+H]⁺.

1-(3-bromophenyl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea **5j**




Following general procedure B compound **5j** was obtained starting from **3d** and isocyanate **4f** as a white solid (167 mg; yield 58%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.23 (d, *J* = 6.9 Hz, 6H, (CH₃)₂CH), 2.89 (hept, *J* = 6.9 Hz, 1H, CH(CH₃)₂), 6.33 (s, 1H, pyrazole), 7.14 (dt, *J* = 1.8, 7.2 Hz, 1H, aromatic), 7.17 – 7.25 (m, 2H, aromatic), 7.38 – 7.43 (m, 1H, aromatic), 7.48 – 7.54 (m, 4H, aromatic), 7.82 (t, *J* = 1.9 Hz, 1H, aromatic), 8.50 (s, 1H, urea), 9.22 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 22.42, 27.64, 40.06, 54.89, 96.29, 116.95, 120.37, 121.72, 124.22, 124.61, 127.29, 129.28, 130.71, 136.95, 138.47, 141.07, 151.55, 158.04.

ESI-MS (*m/z*): theoretical 399.08 [C₁₉H₁₉BrN₄O+H]⁺, experimental 399.72 [C₁₉H₁₉BrN₄O+H]⁺.

1-(isopropyl)-3-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)urea **5i**




Following general procedure B compound **5i** was obtained starting from **3b** and isocyanate **4g** as a white solid (Yield 40%).

¹H NMR (400 MHz, DMSO-*d*₆) δ 1.08 (d, *J* = 6.5 Hz, 6H, N(CH₃)₂CH), 1.19 (s, 9H, (CH₃)₃), 1.30 (d, *J* = 6.6 Hz, 6H, (CH₃)₂CH), 3.71 (hept, 1H, NCH(CH₃)₂), 4.27 (hept, *J* = 6.5 Hz, 1H, CH(CH₃)₂), 5.90 (s, 1H, pyrazole), 6.12 (d, *J* = 7.5 Hz, 1H, NHCH(CH₃)₂), 7.92 (s, 1H, urea).

¹³C NMR (151 MHz, DMSO-*d*₆) δ 22.16, 22.94, 30.47, 41.24, 47.45, 79.19, 93.56, 136.29, 154.06, 158.32, 206.61.

ESI-MS (m/z): theoretical 267.21 [C₁₄H₂₆N₄O+H]⁺, experimental 267.35 [C₁₄H₂₆N₄O+H]⁺.

1-(3-chlorophenyl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea **5m**




Following general procedure B compound **5m** was obtained starting from **3d** and isocyanate **4f** as a white solid (792 mg; yield 31%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.24 (d, *J* = 6.6 Hz, 6H, (CH₃)₂CH), 2.89 (hept, *J* = 6.9 Hz, 1H, CH(CH₃)₂), 6.34 (s, *J* = 2.7 Hz, 1H, pyrazole), 7.02 (dp, *J* = 2.8, 8.1 Hz, 1H, aromatic), 7.14 – 7.23 (m, 1H), 7.28 (td, *J* = 3.4, 7.5, 8.4 Hz, 1H, aromatic), 7.34 – 7.49 (m, 1H, aromatic), 7.53 (q, *J* = 3.3, 3.7 Hz, 4H, aromatic), 7.67 (q, *J* = 2.6 Hz, 1H, aromatic), 8.49 (s, 1H, urea), 9.20 (s, 1H, urea).

¹³C-NMR (101 MHz, DMSO-*d*₆) δ (ppm): 22.44, 27.65, 96.32, 116.62, 117.56, 121.76, 124.26, 127.33, 129.31, 130.44, 133.22, 136.98, 138.49, 140.94, 151.59, 158.08.

ESI-MS (m/z): theoretical 355.13 [C₁₉H₁₉ClN₄O+H]⁺, experimental 355.525 [C₁₉H₁₉ClN₄O+H]⁺.

1-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)-3-(3,5-dimethylphenyl)urea **5n**




Following general procedure B compound **5n** was obtained starting from **3b** and isocyanate **4c** as a white solid (215 mg; yield 91%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.21 (s, 9H, (CH₃)₃), 1.34 (d, *J* = 6.5 Hz, 6H, (CH₃)₂CH), 2.22 (s, 6H, CH₃-aromatic), 4.33 (hept, *J* = 6.3 Hz, 1H, CH(CH₃)₂), 6.01 (s, 1H, pyrazole), 6.62 (s, 1H, aromatic), 7.05 (d, *J* = 1.6 Hz, 2H, aromatic), 8.30 (s, 1H, urea), 8.67 (s, 1H, urea).

¹³C-NMR (101 MHz, DMSO-*d*₆) δ (ppm): 21.12, 22.18, 30.45, 30.70, 31.91, 47.66, 94.17, 115.93, 123.60, 135.48, 137.76, 139.38, 152.11, 158.46.

ESI-MS (m/z): theoretical 329.42 [C₁₉H₂₈N₄O+H]⁺, experimental 329.42 [C₁₉H₂₈N₄O+H]⁺,

1-(3,5-dimethylphenyl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea **5o**




Following general procedure B compound **5o** was obtained starting from **3d** and isocyanate **4c** as a white solid (156 mg; yield 62%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.23 (d, *J* = 6.9 Hz, 6H, (CH₃)₂CH), 2.21 (s, 6H, CH₃-aromatic), 2.88 (p, *J* = 6.9 Hz, 1H, CH(CH₃)₂), 6.33 (s, 1H, pyrazole), 6.61 (s, 1H, aromatic), 7.02 (d, *J* = 1.5 Hz, 2H, aromatic), 7.41 (ddd, *J* = 2.3, 5.6, 7.1 Hz, 1H, aromatic), 7.46 – 7.59 (m, 4H, aromatic), 8.36 (s, 1H, urea), 8.84 (s, 1H, urea).

¹³C-NMR (101 MHz, DMSO-*d*₆) δ (ppm): 21.27, 22.65, 27.83, 96.03, 112.21, 116.17, 122.71, 124.02, 124.48, 127.59, 129.26, 129.56, 137.54, 137.81, 138.08, 138.62, 139.31, 151.81, 158.41.

ESI-MS (m/z): theoretical 349.20 [C₂₁H₂₄N₄O+H]⁺, experimental 349.45 [C₂₁H₂₄N₄O+H]⁺.

1-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)-3-(3-(trifluoromethyl)phenyl)urea **5p**



Following general procedure B compound **5p** was obtained starting from **3d** and isocyanate **4d** as a white solid (280 mg; yield 10%).


¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.24 (d, *J* = 6.6 Hz, 6H, (CH₃)₂CH), 2.89 (hept, *J* = 4.9, 7.4 Hz, 1H, CH(CH₃)₃), 6.35 (s, 1H, pyrazole), 7.31 (d, *J* = 6.4 Hz, 1H, aromatic), 7.41 (dd, *J* = 3.7, 7.4

Hz, 1H, aromatic), 7.47 – 7.57 (m, 6H, aromatic), 7.97 (d, $J = 5.6$ Hz, 1H, aromatic), 8.53 (s, 1H, urea), 9.37 (s, 1H, urea).

$^{13}\text{C-NMR}$ (101 MHz, $\text{DMSO-}d_6$) δ (ppm): 22.45, 27.67, 30.71, 96.49, 121.79, 122.41, 124.25, 127.34, 128.98, 129.31, 129.99, 136.90, 138.49, 140.27, 151.75, 158.10.

ESI-MS (m/z): theoretical 389.15 $[\text{C}_{20}\text{H}_{19}\text{F}_3\text{N}_4\text{O}+\text{H}]^+$, experimental 389.44 $[\text{C}_{20}\text{H}_{19}\text{F}_3\text{N}_4\text{O}+\text{H}]^+$.

1-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)-3-(3-(trifluoromethyl)phenyl)urea **5q**




Following general procedure B compound **5q** was obtained starting from **3b** and isocyanate **4d** as a white solid (154 mg; yield 58%).

$^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 1.22 (s, 9H, $(\text{CH}_3)_3$), 1.34 (d, $J = 6.6$ Hz, 6H, $(\text{CH}_3)_2\text{CH}$), 4.36 (hept, $J = 6.6$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 6.02 (s, 1H, pyrazole), 7.26 – 7.36 (m, 1H, aromatic), 7.51 (t, $J = 7.9$ Hz, 1H, aromatic), 7.54 – 7.62 (m, 1H, aromatic), 8.00 (d, $J = 2.1$ Hz, 1H, aromatic), 8.44 (s, 1H, urea), 9.22 (s, 1H, urea).

$^{13}\text{C-NMR}$ (101 MHz, $\text{DMSO-}d_6$) δ (ppm): 22.14, 30.38, 31.88, 47.72, 95.01, 114.12, 118.21, 121.80, 129.32, 129.63, 129.92, 134.90, 140.39, 152.35, 158.53.

ESI-MS (m/z): theoretical 369.19 $[\text{C}_{18}\text{H}_{23}\text{F}_3\text{N}_4\text{O}+\text{H}]^+$, experimental 369.44 $[\text{C}_{18}\text{H}_{23}\text{F}_3\text{N}_4\text{O}+\text{H}]^+$.

1-(4-bromophenyl)-3-(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)urea **5r**



Following general procedure B compound **5r** was obtained starting from **3g** and isocyanate **4f** as a white solid (189 mg; yield 66%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 0.66 – 0.71 (m, 2H, (CH₂)₂CH), 0.85 – 0.91 (m, 2H, (CH₂)₂CH), 1.88 (tt, *J* = 5.0, 8.4 Hz, 1H, CH(CH₂)₂), 6.16 (s, 1H, pyrazole), 7.34 – 7.45 (m, 5H, aromatic), 7.48 – 7.54 (m, 4H, aromatic), 8.44 (s, 1H, urea), 9.12 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 7.70, 9.38, 95.60, 113.51, 120.11, 120.23, 124.20, 127.29, 129.29, 131.53, 137.19, 138.41, 138.79, 151.50, 152.27, 154.30.

ESI-MS (*m/z*): theoretical 397.06 [C₁₉H₁₇BrN₄O+H]⁺, experimental 397.51 [C₁₉H₁₇BrN₄O+H]⁺.

1-(4-bromophenyl)-3-(3-cyclopropyl-1-isopropyl-1H-pyrazol-5-yl)urea **5s**




Following general procedure B compound **5s** was obtained starting from **3h** and isocyanate **4e** as a white solid (186 mg; yield 71%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 0.49 – 0.61 (m, 2H, (CH₂)₂CH), 0.77 – 0.84 (m, 2H, (CH₂)₂CH), 1.32 (d, *J* = 6.6 Hz, 6H, (CH₃)₂CH), 1.80 (tt, *J* = 5.0, 8.4 Hz, 1H, CH(CH₂)₂), 4.32 (hept, *J* = 6.6 Hz, 1H, CH(CH₂)₃), 5.77 (s, 1H, pyrazole), 7.23 – 7.72 (m, 4H, aromatic), 8.43 (s, 1H, urea), 8.97 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 7.56, 9.66, 14.08, 22.21, 47.59, 59.75, 94.05, 113.39, 120.15, 131.51, 135.51, 135.52, 138.96, 138.97, 152.00, 152.11.

ESI-MS (*m/z*): theoretical 365.08 [C₁₆H₁₉BrN₄O+H]⁺, experimental 365.54 [C₁₆H₁₉BrN₄O+H]⁺.

1-(4-bromophenyl)-3-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)urea **5t**




Following general procedure B compound **5t** was obtained starting from **3f** and isocyanate **4e** as a white solid (202 mg; yield 83%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.16 (d, *J* = 6.9 Hz, 6H, (CH₃)₂CH), 2.77 (hept, *J* = 6.9 Hz, 1H, CH(CH₃)₂), 3.58 (s, 3H, NCH₃), 5.99 (s, 1H, pyrazole), 7.51 – 7.31 (m, 4H, aromatic), 8.53 (s, 1H, urea), 9.02 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 22.62, 27.51, 34.88, 40.06, 94.38, 113.43, 120.14, 131.53, 136.93, 138.94, 151.77, 155.72.

ESI-MS (*m/z*): theoretical 337.06 [C₁₄H₁₇BrN₄O+H]⁺, experimental 337.43 [C₁₄H₁₇BrN₄O+H]⁺.

1-(4-bromophenyl)-3-(3-(tert-butyl)-1-methyl-1H-pyrazol-5-yl)urea **5u**




Following general procedure B compound **5u** was obtained starting from **3c** and isocyanate **4e** as a white solid (187 mg; yield 74%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.21 (s, 9H, (CH₃)₃), 3.59 (s, 3H, NCH₃), 6.04 (s, 1H, pyrazole), 7.55 – 7.36 (m, 5H, aromatic), 8.50 (s, 1H, urea), 9.02 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 30.37, 31.80, 34.93, 54.92, 93.96, 113.43, 115.74, 120.14, 131.54, 136.84, 138.95, 151.80, 152.27, 158.54.

ESI-MS (*m/z*): theoretical 353.07 [C₁₅H₁₉BrN₄O+H]⁺, experimental 353.18 [C₁₅H₁₉BrN₄O+H]⁺.

1-(3-bromophenyl)-3-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)urea **5v**




Following general procedure B compound **5v** was obtained starting from **3f** and isocyanate **4f** as a white solid (124 mg; yield 51%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.16 (d, *J* = 6.9 Hz, 6H, (CH₃)₂CH), 2.78 (hept, 1H, CH(CH₃)₂), 3.59 (s, 3H, CH₃), 6.01 (s, 1H, pyrazole), 7.16 (m, 1H, aromatic), 7.24 (m, 1H, aromatic), 7.34 – 7.28 (m, 1H, aromatic), 7.85 (m, 1H, aromatic), 8.62 (s, 1H, urea), 9.13 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 22.63, 27.52, 34.89, 94.48, 117.06, 117.23, 120.59, 121.72, 124.57, 130.74, 136.84, 141.21, 151.79, 155.76.

ESI-MS (m/z): theoretical 337.06 [C₁₄H₁₇BrN₄O+H]⁺, experimental 337.49 [C₁₄H₁₇BrN₄O+H]⁺.

1-(4-bromophenyl)-3-(1,3-diisopropyl-1H-pyrazol-5-yl)urea **5x**




Following general procedure B compound **5x** was obtained starting from **3e** and isocyanate **4e** as a white solid (184 mg; yield 70%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.16 (d, *J* = 6.9 Hz, 6H, (CH₃)₂CH), 1.33 (d, *J* = 6.5 Hz, 6H, (CH₃)₂CHN), 2.80 (hept, *J* = 6.9 Hz, 1H, CH(CH₃)₂), 4.35 (hept, 1H, NCH(CH₃)₂), 5.96 (s, 1H, pyrazole), 7.43 (s, 4H, aromatic), 8.52 (s, 1H, urea), 9.10 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 22.23, 22.75, 27.71, 47.59, 79.17, 94.84, 113.21, 120.08, 131.47, 135.49, 139.20, 152.29, 155.80.

ESI-MS (m/z): theoretical 367.09 [C₁₆H₂₁BrN₄O+H]⁺, experimental 367.08 [C₁₆H₂₁BrN₄O+H]⁺.

1-(3,2-aminophenylbromophenyl)-3-(1,3-diisopropyl-1H-pyrazol-5-yl)urea **5y**



Following general procedure B compound **5y** was obtained starting from **3e** and isocyanate **4f** as a white solid (132 mg; yield 50%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.16 (d, *J* = 6.9 Hz, 6H, (CH₃)₂CH), 1.33 (d, *J* = 6.5 Hz, 6H, (CH₃)₂CHN), 2.80 (hept, *J* = 6.9 Hz, 1H, CH(CH₃)₂), 4.35 (hept, 1H, NCH(CH₃)₂), 5.98 (s, 1H, pyrazole), 7.15 (m, 1H, aromatic), 7.23 (m, 1H, aromatic), 7.30 (m, 1H, aromatic), 7.84 (m, 1H, aromatic), 8.43 (s, 1H, urea), 9.03 (s, 1H, urea).


¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 14.10, 22.23, 22.75, 27.72, 47.66, 59.77, 79.18, 95.06, 117.06, 120.45, 121.71, 124.54, 130.74, 135.21, 141.26, 152.16, 155.88.

ESI-MS (m/z): theoretical 367.09 [C₁₆H₂₁BrN₄O+H]⁺, experimental 367.08 [C₁₆H₂₁BrN₄O+H]⁺.

General procedure C

Boronic acid **7a-d** (1.40 mmol), bromoaniline **6a-b** (1.16 mmol) and Pd(PPh₃)₄ (0.04 mmol) were dissolved in a degassed 1:1 solution of 2M K₂CO₃:DMF (4.4 mL). The reaction mixture was stirred at 100° for 15h under Argon atmosphere. After cooling, the reaction solution was extracted with EtOAc (100 mL) and washed with H₂O (2x100mL) and brine (100mL). The organic layer was dried with Na₂SO₄ and filtered. The solvent was removed under vacuum and the crude was purified by column chromatography.

2'-methoxy-[1,1'-biphenyl]-4-amine **8a**




Following general procedure B compound **8a** was obtained starting from **7a** and **6a**. **7a** was purified by column chromatography (Silica, petroleum ether:EtOAc, 5:1 → 0:1, R_f = 0.41). Concentration in vacuo of the product-rich fractions gave **8a** as yellow oily liquid (141 mg; yield 61%).

¹H-NMR (400 MHz, Chloroform-*d*) δ (ppm): 3.81 (s, 3H, OCH₃), 6.80 – 6.72 (m, 2H, aromatic), 7.05 – 6.93 (m, 2H, aromatic), 7.33 – 7.23 (m, 2H, aromatic), 7.42 – 7.33 (m, 2H, aromatic).

¹³C-NMR (101 MHz, Chloroform-*d*) δ (ppm): 55.69, 111.35, 111.41, 114.95, 114.98, 120.95, 121.05, 127.93, 128.76, 128.95, 129.00, 130.60, 130.67, 130.89, 145.37, 145.44, 156.63.

ESI-MS (m/z): theoretical 200.25 [C₁₃H₁₃NO+H]⁺, experimental 200.21 [C₁₃H₁₃NO+H]⁺

1-(4'-amino-[1,1'-biphenyl]-3-yl)ethan-1-one **8b**




Following general procedure B compound **8b** was obtained starting from **6a** and **7c**. **8b** was purified by column chromatography (Silica, petroleum ether:EtOAc, 5:1 → 1:1, $R_f = 0.28$). Concentration in vacuo of the product-rich fractions gave **8b** as yellow oily liquid (157 mg; yield 64%).

¹H-NMR (400 MHz, DMSO- d_6) δ (ppm): 2.63 (s, 3H, CH₃), 6.61 – 6.74 (m, 2H, aromatic), 7.38 – 7.47 (m, 2H, aromatic), 7.51 (t, $J = 7.8$ Hz, 1H, aromatic), 7.79 (dt, $J = 1.7, 7.9$ Hz, 2H, aromatic), 8.06 (t, $J = 1.9$ Hz, 1H, aromatic).

¹³C-NMR (101 MHz, DMSO- d_6) δ (ppm): 55.47, 55.60, 66.36, 109.52, 112.31, 114.36, 117.39, 126.88, 127.91, 133.80, 147.28, 147.42, 148.98.

ESI-MS (m/z): theoretical 212.10 [C₁₄H₁₃NO+H]⁺, experimental 212.19 [C₁₄H₁₃NO+H]⁺.

4'-methoxy-[1,1'-biphenyl]-4-amine **8c**




Following general procedure B compound **8c** was obtained starting from **6a** and **7d**. **8c** was purified by column chromatography (Silica, petroleum ether:EtOAc, 5:1 → 1:1, $R_f = 0.32$). Concentration in vacuo of the product-rich fractions gave **8c** as yellow oily liquid (118 mg, yield 51%).

¹H-NMR (600 MHz, DMSO- d_6) δ (ppm): 3.75 (s, 3H, OCH₃), 5.10 (s, 2H, aromatic), 6.63 – 6.58 (m, 2H, aromatic), 6.96 – 6.90 (m, 2H, aromatic), 7.30 – 7.25 (m, 2H, aromatic), 7.47 – 7.41 (m, 2H, aromatic).

¹³C-NMR (151 MHz, DMSO- d_6) δ (ppm): 55.08, 114.16, 114.26, 126.42, 126.69, 127.40, 133.35, 147.71, 157.64.

ESI-MS (m/z): theoretical 200.25 [C₁₃H₁₃NO+H]⁺, experimental 200.19 [C₁₃H₁₃NO+H]⁺.

4'-methoxy-[1,1'-biphenyl]-3-amine **8d**




Following general procedure B compound **8d** was obtained starting from **6b** and **7a**. **8d** was purified by column chromatography (Silica, petroleum ether:EtOAc, 5:1 → 1:1, $R_f = 0.41$). Concentration in vacuo of the product-rich fractions gave **8d** as dark orange oily liquid (185 mg; yield 80%).

¹H-NMR (400 MHz, Chloroform-*d*) δ (ppm): 3.85 (s, 3H, OCH₃), 6.64 (ddd, $J = 7.9, 2.4, 1.0$ Hz, 1H, aromatic), 6.87 (t, $J = 2.1$ Hz, 1H, aromatic), 6.96 (m, 3H, aromatic), 7.20 (t, $J = 7.8$ Hz, 1H, aromatic), 7.50 (m, 2H, aromatic).

¹³C-NMR (101 MHz, Chloroform-*d*) δ (ppm): 21.18, 55.48, 60.53, 113.67, 113.70, 114.22, 117.47, 128.23, 129.78, 134.09, 142.19, 146.84, 159.26.

ESI-MS (m/z): theoretical 200.25 [C₁₃H₁₃NO+H]⁺, experimental 200.22 [C₁₃H₁₃NO+H]⁺.

3',4'-dimethoxy-[1,1'-biphenyl]-3-amine **8e**




Following general procedure B compound **8e** was obtained starting from **6b** and **7b**. **8e** was purified by column chromatography (Silica, petroleum ether: EtOAc, 5:1 → 0:1, $R_f = 0.41$). Concentration in vacuo of the product-rich fractions gave **8e** as light-yellow solid (160 mg; yield 60%).

¹H-NMR (400 MHz, Chloroform-*d*) δ (ppm): 3.91 (s, 3H, OCH₃), 3.94 (s, 3H, OCH₃), 6.95 – 6.89 (m, 3H, aromatic), 7.10 – 7.04 (m, 2H, aromatic), 7.44 – 7.39 (m, 2H, aromatic).

¹³C-NMR (101 MHz, Chloroform-*d*) δ (ppm): 56.10, 56.14, 110.65, 111.57, 114.54, 114.61, 118.55, 119.51, 129.87, 134.39, 142.55, 145.29, 148.80, 149.22.

ESI-MS (m/z): theoretical 230.28 [C₁₄H₁₅NO₂+H]⁺, experimental 230.23 [C₁₄H₁₅NO₂+H]⁺.

1-(3'-amino-[1,1'-biphenyl]-3-yl)ethan-1-one **8f**



Following general procedure B compound **8f** was obtained starting from **6b** and **7c**. **AG06** was purified by column chromatography (Silica, petroleum ether:EtOAc, 5:1 → 1:1, $R_f = 0.50$). Concentration in vacuo of the product-rich fractions gave **8f** as yellow oily liquid (184 mg; yield 75%).

¹H-NMR (400 MHz, Chloroform-*d*) δ (ppm): 2.65 (s, 3H, CH₃), 6.72 (ddd, J = 8.0, 2.4, 1.0 Hz, 1H, aromatic), 6.94 (t, J = 2.0 Hz, 1H, aromatic), 7.25 (t, J = 7.8 Hz, 1H, aromatic), 7.01 (ddd, J = 7.7, 1.7, 1.0 Hz, 1H, aromatic), 7.51 (t, J = 7.7 Hz, 1H, aromatic), 7.76 (ddd, J = 7.8, 1.9, 1.1 Hz, 1H, aromatic), 7.92 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H, aromatic), 8.15 (t, J = 1.9 Hz, 1H, aromatic).


¹³C-NMR (101 MHz, Chloroform-*d*) δ (ppm): 26.90, 113.95, 114.70, 117.73, 127.08, 127.28, 129.06, 130.01, 131.85, 137.68, 141.53, 142.04, 147.04, 198.31.

ESI-MS (m/z): theoretical 212.26 [C₁₄H₁₃NO+H]⁺, experimental 212.19 [C₁₄H₁₃NO+H]⁺.

General procedure D

Pyrazole **3a,b,d** (0.26 mmol) and Et₃N (0.6 mmol) dissolved in anhydrous DCM (0.9 mL) was added dropwise to a solution of triphosgene (0.10 mmol) in anhydrous DCM (0.5 mL), at 0°C under Argon atmosphere and under magnetic stirring. After 30 min, aniline **8a-f** (0.26 mmol) and Et₃N (0.6 mmol) dissolved in anhydrous DCM (0.5 mL) was added dropwise. The reaction mixture was stirred at room temperature overnight under Argon atmosphere. The crude was extracted with EtOAc (50 mL) and washed with saturated NaHCO₃ (2x50mL) and brine (50mL). The organic layer was dried with Na₂SO₄ and filtered. Removal of the volatiles in vacuo provided a residue, which was purified by column chromatography to afford ureas **9a-f** and **10 a-c**.

1-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)-3-(4'-methoxy-[1,1'-biphenyl]-4-yl)urea **10a**




Following general procedure D compound **10a** was obtained starting from **8a** and **3d**. **10a** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, R_f = 0.58). Concentration in vacuo of the product-rich fractions gave **10a** as white solid (33 mg; yield 30%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.24 (d, J = 6.9 Hz, 6H, CH(CH₃)₂), 2.89 (hept, J = 6.9 Hz, 1H, CH(CH₃)₂), 3.78 (s, 3H, CH₃), 6.34 (s, 1H, pyrazole), 7.02 – 6.96 (m, 2H, aromatic), 7.48 – 7.38 (m, 3H, aromatic), 7.58 – 7.49 (m, 8H, aromatic), 8.45 (s, 1H, urea), 9.09 (s, 1H, urea).

¹³C-NMR (101 MHz, DMSO-*d*₆) δ (ppm): 14.08, 20.76, 22.44, 27.65, 54.90, 55.14, 59.75, 95.91, 114.31, 118.54, 124.29, 126.47, 127.19, 127.29, 129.30, 132.23, 133.63, 137.31, 138.23, 138.53, 151.59, 158.05, 158.48, 170.35.

ESI-MS (m/z): theoretical 427.52 [C₂₆H₂₆N₄O₂+H]⁺, experimental 427.48 [C₂₆H₂₆N₄O₂+H]⁺.

1-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)-3-(2'-methoxy-[1,1'-biphenyl]-4-yl)urea 10b




Following general procedure D compound **10b** was obtained starting from **3d** and **8c**. **10b** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, R_f = 0.10). Concentration in vacuo of the product-rich fractions gave **10b** as white solid (52 mg; yield 47%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.24 (d, *J* = 7.0 Hz, 6H, (CH₃)₂CH), 2.89 (hept, *J* = 6.9 Hz, 1H, CH(CH₃)₂), 3.75 (s, 3H, CH₃), 6.35 (s, 1H, pyrazole), 7.00 (td, *J* = 1.1, 7.4 Hz, 1H, aromatic), 7.08 (d, *J* = 8.2 Hz, 1H, aromatic), 7.27 (ddd, *J* = 13.9, 7.1, 1.5 Hz, 2H, aromatic), 7.35 – 7.46 (m, 5H, aromatic), 7.54 (d, *J* = 3.8 Hz, 4H, aromatic), 8.44 (s, 1H, urea), 9.07 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 22.51, 27.70, 55.51, 59.83, 95.96, 111.77, 113.46, 117.82, 120.83, 122.46, 124.35, 125.64, 127.38, 128.50, 129.37, 129.49, 129.69, 130.16, 131.98, 137.36, 138.21, 138.56, 151.69, 156.15, 158.12.

ESI-MS (m/z): theoretical 427.52 [C₂₆H₂₆N₄O₂+H]⁺, experimental 427.45 [C₂₆H₂₆N₄O₂+H]⁺.

1-(3'-acetyl-[1,1'-biphenyl]-4-yl)-3-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)urea 10c




Following general procedure D compound **10c** was obtained starting from **3b** and **8b**. **10r** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, $R_f = 0.24$). Concentration in vacuo of the product-rich fractions gave the title compound as white solid (46 mg; yield 42%).

$^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 1.23 (s, 9H, $(\text{CH}_3)_3$), 1.35 (d, $J = 6.5$ Hz, 6H, $(\text{CH}_2)_2 \text{CH}_3$), 2.65 (s, 3H, OCH_3), 4.36 (hept, $J = 6.5$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 6.03 (s, 1H, pyrazole), 7.51 – 7.64 (m, 3H, aromatic), 7.65 – 7.72 (m, 2H, aromatic), 7.86 – 7.94 (m, 2H, aromatic), 8.16 (t, $J = 1.8$ Hz, 1H, aromatic), 8.37 (s, 1H, urea), 9.01 (s, 1H, urea).

$^{13}\text{C-NMR}$ (151 MHz, $\text{DMSO-}d_6$) δ (ppm): 22.23, 26.96, 30.45, 30.48, 31.95, 47.75, 94.61, 118.59, 125.75, 126.56, 127.30, 129.38, 130.80, 132.76, 135.24, 135.31, 137.51, 139.58, 140.25, 152.23, 158.53, 198.16.

ESI-MS (m/z): theoretical 419.54 $[\text{C}_{25}\text{H}_{30}\text{N}_4\text{O}_2+\text{H}]^+$, experimental 419.46 $[\text{C}_{25}\text{H}_{30}\text{N}_4\text{O}_2+\text{H}]^+$.

1-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)-3-(4'-methoxy-[1,1'-biphenyl]-3-yl)urea **9a**




Following general procedure D compound **9a** was obtained starting from **3d** and **8d**. **9a** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, $R_f = 0.49$). Concentration in vacuo of the product-rich fractions gave **9a** as white solid (29 mg; yield 26%).

$^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 1.24 (d, $J = 6.9$ Hz, 6H, $(\text{CH}_3)_2\text{CH}$), 2.88 (hept, $J = 7.0$ Hz, $\text{CH}(\text{CH}_3)_2$), 3.79 (s, 3H, OCH_3), 6.35 (s, 1H, pyrazole), 7.05 – 6.99 (m, 2H, aromatic), 7.21 (dt, $J = 6.9, 1.9$ Hz, 1H, aromatic), 7.35 – 7.27 (m, 2H, aromatic), 7.45 – 7.39 (m, 1H, aromatic), 7.57 – 7.51 (m, 6H, aromatic), 7.70 (m, 1H, aromatic), 8.44 (s, 1H, urea), 9.08 (s, 1H, urea).

$^{13}\text{C-NMR}$ (101 MHz, $\text{DMSO-}d_6$) δ (ppm): 22.47, 27.67, 40.06, 55.19, 95.86, 114.38, 115.95, 116.59, 120.13, 124.35, 127.34, 127.70, 129.33, 129.36, 132.55, 137.31, 138.51, 139.91, 140.52, 151.67, 158.08, 158.97.

ESI-MS (m/z): theoretical 427.52 $[\text{C}_{26}\text{H}_{26}\text{N}_4\text{O}_2+\text{H}]^+$, experimental 427.45 $[\text{C}_{26}\text{H}_{26}\text{N}_4\text{O}_2+\text{H}]^+$.

1-(3',4'-dimethoxy-[1,1'-biphenyl]-3-yl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea **9b**




Following general procedure D compound **9b** was obtained starting from **3d** and **8e**. **9b** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, $R_f = 0.40$). Concentration in vacuo of the product-rich fractions gave **9b** as white solid (50 mg; yield 42%).

$^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 1.24 (d, $J = 6.9$ Hz, 6H, $(\text{CH}_3)_2\text{CH}$), 2.89 (hept, $J = 6.9$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 3.79 (s, 3H, CH_3), 3.83 (s, 3H, CH_3), 6.35 (s, 1H, pyrazole), 7.03 (d, $J = 8.2$ Hz, 1H, aromatic), 7.17 – 7.09 (m, 2H, aromatic), 7.24 (dt, $J = 7.5, 1.5$ Hz, 1H, aromatic), 7.32 (t, $J = 7.8$ Hz, 1H, aromatic), 7.38 (dt, $J = 8.1, 1.5$ Hz, 1H, aromatic), 7.50 – 7.38 (m, 1H, aromatic), 7.54 (m, 4H, aromatic), 7.62 (t, $J = 1.9$ Hz, 1H, aromatic), 8.45 (s, 1H, urea), 9.09 (s, 1H, urea).

$^{13}\text{C-NMR}$ (101 MHz, $\text{DMSO-}d_6$) δ (ppm): 22.45, 27.65, 39.92, 40.06, 55.55, 55.57, 95.84, 110.35, 112.17, 116.12, 116.67, 118.80, 120.38, 124.34, 127.31, 129.26, 129.30, 132.95, 137.30, 138.50, 139.83, 140.81, 151.65, 158.04.

ESI-MS (m/z): theoretical 457.55 [$\text{C}_{27}\text{H}_{28}\text{N}_4\text{O}_3 + \text{H}$] $^+$, experimental 457.48 [$\text{C}_{27}\text{H}_{28}\text{N}_4\text{O}_3 + \text{H}$] $^+$.

1-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)-3-(4'-methoxy-[1,1'-biphenyl]-3-yl)urea **9c**



Following general procedure D compound **9c** was obtained starting from **3b** and **8d**. **9c** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, $R_f = 0.45$). Concentration in vacuo of the product-rich fractions gave **9c** as white solid (18 mg; yield 17%).


$^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm): 1.21 (s, 9H, CH_3), 1.33 (d, $J = 6.6$ Hz, 6H, $(\text{CH}_3)_2\text{CH}$), 3.78 (s, 3H, CH_3), 4.35 (hept, $J = 6.7$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 6.01 (s, 1H, pyrazole), 7.06 – 6.98 (m, 2H,

aromatic), 7.25 – 7.17 (m, 1H, aromatic), 7.37 – 7.28 (m, 2H, aromatic), 7.58 – 7.50 (m, 2H, aromatic), 7.72 (q, $J = 1.5$ Hz, 1H, aromatic), 8.35 (s, 1H, urea), 8.90 (s, 1H, urea).

$^{13}\text{C-NMR}$ (151 MHz, $\text{DMSO-}d_6$) δ (ppm): 22.37, 30.66, 48.01, 55.42, 94.99, 114.61, 116.25, 116.94, 120.33, 127.95, 129.63, 132.78, 135.51, 140.22, 159.18, 140.74, 152.64, 158.88,

ESI-MS (m/z): theoretical 407.53 [$\text{C}_{24}\text{H}_{30}\text{N}_4\text{O}_2+\text{H}$] $^+$, experimental 407.24 [$\text{C}_{24}\text{H}_{30}\text{N}_4\text{O}_2+\text{H}$] $^+$.

1-(3'-acetyl-[1,1'-biphenyl]-3-yl)-3-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)urea **9d**




Following general procedure C compound **9d** was obtained starting from **3b** and **8f**. **9d** was purified by column chromatography (Silica, $\text{DCM}:\text{EtOAc}$ 98:2 \rightarrow 9:1, $R_f = 0.49$). Concentration in vacuo of the product-rich fractions gave **9d** as white solid (25 mg; yield 23%).

$^1\text{H-NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ (ppm): 1.22 (s, 9H, CH_3), 1.34 (d, $J = 6.7$ Hz, 6H, $(\text{CH}_3)_2\text{CH}$), 2.65 (s, 3H, CH_3), 4.38 (hept, $J = 6.5$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 6.02 (s, 1H, pyrazole), 7.34 (dt, $J = 1.5, 7.6$ Hz, 1H, aromatic), 7.41 (t, $J = 7.8$ Hz, 1H, aromatic), 7.47 (d, $J = 8.2$ Hz, 1H, aromatic), 7.63 (t, $J = 7.7$ Hz, 1H, aromatic), 7.83 (t, $J = 2.0$ Hz, 1H), 7.89 (dt, $J = 1.5, 7.8$ Hz, 1H), 7.97 (dt, $J = 1.4, 7.7$ Hz, 1H, aromatic), 8.14 (d, $J = 2.0$ Hz, 1H, aromatic), 8.45 (s, 1H, urea), 9.06 (s, 1H, urea).

$^{13}\text{C-NMR}$ (151 MHz, $\text{DMSO-}d_6$) δ (ppm): 20.82, 22.24, 26.95, 30.50, 47.76, 54.94, 59.83, 94.67, 116.59, 117.80, 120.65, 126.11, 127.45, 129.51, 129.63, 131.35, 135.36, 137.50, 140.00, 140.36, 140.71, 152.42, 158.56, 198.07.

ESI-MS (m/z): theoretical 419.54 [$\text{C}_{25}\text{H}_{30}\text{N}_4\text{O}_2+\text{H}$] $^+$, experimental 419.27 [$\text{C}_{25}\text{H}_{30}\text{N}_4\text{O}_2+\text{H}$] $^+$.

1-(3'-acetyl-[1,1'-biphenyl]-3-yl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea **9e**




Following general procedure D compound **9e** was obtained starting from **3a** and **8f**. **9e** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, $R_f = 0.35$). Concentration in vacuo of the product-rich fractions gave **9e** as white solid (12 mg; yield 10%).

¹H-NMR (600 MHz, DMSO- d_6) δ (ppm): 1.29 (s, 9H, CH₃), 5.75 (s, 3H, OCH₃), 6.40 (s, 1H, pyrazole), 7.44 – 7.30 (m, 3H, aromatic), 7.52 – 7.41 (m, 1H, aromatic), 7.54 (d, $J = 4.3$ Hz, 4H, aromatic), 7.70 – 7.59 (m, 1H, aromatic), 7.80 (s, 1H, aromatic), 7.92 – 7.84 (m, 1H, aromatic), 7.97 (dt, $J = 7.8, 1.3$ Hz, 1H, aromatic), 8.13 (t, $J = 1.8$ Hz, 1H, aromatic), 8.46 (s, 1H, urea), 9.19 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO- d_6) δ (ppm): 26.96, 30.26, 54.95, 95.75, 116.55, 117.75, 120.81, 122.52, 124.16, 124.39, 126.10, 127.38, 127.50, 129.32, 129.38, 129.53, 129.69, 131.38, 137.17, 137.51, 138.61, 140.04, 140.17, 140.67, 151.81, 160.91, 198.11.

ESI-MS (m/z): theoretical 453.56 [C₂₈H₂₈N₄O₂+H]⁺, experimental 453.20 [C₂₈H₂₈N₄O₂+H]⁺.

1-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)-3-(3',4'-dimethoxy-[1,1'-biphenyl]-3-yl)urea **9f**



Following general procedure D compound **9f** was obtained starting from **8e** and **3b**. **9f** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, $R_f = 0.44$). Concentration in vacuo of the product-rich fractions gave **9f** as white solid (68 mg; yield 60%).

¹H-NMR (600 MHz, DMSO- d_6) δ (ppm): 1.34 (d, $J = 6.5$ Hz, 6H, (CH₃)₂CH), 3.79 (s, 3H, OCH₃), 3.83 (s, 3H, OCH₃), 4.38 (hept, $J = 6.6$ Hz, 1H, CH(CH₃)₂), 6.02 (s, 1H, pyrazole), 7.04 (d, $J = 8.4$ Hz, 1H, aromatic), 7.18 – 7.12 (m, 2H, aromatic), 7.24 (ddd, $J = 7.7, 1.8, 1.0$ Hz, 1H, aromatic), 7.33 (t, $J = 7.9$ Hz, 1H, aromatic), 7.41 (ddd, $J = 8.1, 2.1, 1.0$ Hz, 1H, aromatic), 7.69 (t, $J = 2.0$ Hz, 1H, aromatic), 1.22 (s, 9H, CH₃), 8.54 (s, 1H, urea), 9.08 (s, 1H, urea).


¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 14.09, 20.77, 22.20, 30.46, 31.91, 47.66, 59.75, 94.49, 110.37, 112.18, 116.16, 116.72, 118.79, 120.19, 129.22, 133.04, 135.44, 140.12, 140.78, 148.56, 149.01, 152.37, 158.43.

ESI-MS (m/z): theoretical 437.56 [C₂₅H₃₂N₄O₃+H]⁺, experimental 437.28 [C₂₅H₃₂N₄O₃+H]⁺.

General procedure E

Bromo urea **5f-k**, **5r-x** (0.26 mmol), boronic acid **7a-d** (0.53 mmol) and Pd(dppf)Cl₂ (0.016 mmol) were dissolved in a degassed solution of 1:2 2M Na₂CO₃:1,4-dioxane (2 mL) and placed in a microwave reaction via under Argon atmosphere. The reaction mixture was heated for 1 hour at 100 °C under MW irradiation and then left to cool for 10 minutes. After cooling, the reaction solution was extracted with EtOAc (50 mL), washed with saturated NaHCO₃ (2x50 mL) and brine (1x 50 mL) and finally dried on Na₂SO₄. Volatiles were removed under vacuum and the resulting crude was purified by column chromatography to afford compounds **9g-i** and **10d-s**.

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(4'-methoxy-[1,1'-biphenyl]-3-yl)urea **9g**




Following general procedure E compound **9g** was obtained starting from **5g**. **9g** was purified by column chromatography (Silica, DCM:EtOAc 95:5 → 1:1, R_f = 0.64) Concentration in vacuo of the product-rich fractions gave an impure white solid which was decanted in diethyl ether (10 mL) overnight. This was filtered and dried in vacuo, of which the solid phase gave the title product as a white powder (41 mg; yield 36%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.29 (s, 9H, (CH₃)₃C), 3.79 (s, 3H, OMe), 6.40 (s, 1H, pyrazole), 7.02 (m, 2H, aromatic), 7.21 (m, 1H, aromatic), 7.34 – 7.24 (m, 2H, aromatic), 7.46 – 7.38 (m, 1H, aromatic), 7.57 – 7.51 (m, 6H, aromatic), 7.71 (m, 1H, aromatic), 8.43 (s, 1H, urea), 9.10 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 14.15, 20.83, 30.26, 55.24, 59.85, 95.62, 114.43, 115.99, 124.40, 127.37, 127.76, 129.38, 137.23, 138.61, 151.77, 159.01, 160.89.

ESI-MS (m/z): theoretical 441.22 [C₂₇H₂₈N₄O₂+H]⁺, experimental 441.50 [C₂₇H₂₈N₄O₂+H]⁺.

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3',4'-dimethoxy-[1,1'-biphenyl]-3-yl)urea **9h**




Following general procedure E compound **9h** was obtained starting from **5g**. **9h** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, R_f = 0.39). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (56 mg; yield 46%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): δ 1.28 (s, 9H, (CH₃)₃), 3.79 (s, 3H, OMe), 3.82 (s, 3H, OMe), 6.39 (s, 1H, pyrazole), 7.03 (m, 1H, aromatic), 7.12 (m, 1H, aromatic), 7.14 (m, 1H, aromatic), 7.24 (m, 1H, aromatic), 7.32 (m, 1H, aromatic), 7.37 (m, 1H, aromatic), 7.42 (m, 1H, aromatic), 7.54 (m, 4H, aromatic), 7.62 (m, 1H, aromatic), 8.43 (s, 1H, urea), 9.10 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 30.23, 32.08, 40.43, 55.58, 55.60, 95.57, 112.20, 116.14, 116.69, 118.84, 120.42, 124.37, 127.32, 129.31, 129.33, 132.99, 137.21, 138.58, 139.87, 140.85, 148.60, 149.03, 151.72, 160.83.

ESI-MS (m/z): theoretical 471.57 [C₂₈H₃₀N₄O₃+H]⁺, experimental 471.56 [C₂₈H₃₀N₄O₃+H]⁺.

1-(3',4'-dimethoxy-[1,1'-biphenyl]-3-yl)-3-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)urea **9i**




Following general procedure E compound **9i** was obtained starting from **5v**. **9i** was purified by column chromatography (Silica, DCM:EtOAc 9:1 → 1:1, R_f = 0.63). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (42 mg; yield 41%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.16 (d, 6H, J = 8 Hz, (CH₃)₂CH), 2.78 (m, 1H, CH(CH₃)₂), 3.60 (s, 3H, NCH₃), 3.79 (s, 3H, OCH₃), 3.84 (s, 3H, OCH₃), 6.02 (s, 1H, pyrazole), 7.04 (m, 1H, aromatic), 7.18 – 7.10 (m, 2H, aromatic), 7.26 (m, 1H, aromatic), 7.34 (t, J = 7.8 Hz, 1H, aromatic), 7.46 – 7.37 (m, 1H, aromatic), 7.68 (m, 1H, aromatic), 8.52 (s, 1H, urea), 8.93 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 22.64, 27.53, 34.87, 55.57 (d, *J* = 4.5. Hz), 94.17, 110.37, 112.19, 116.21, 116.77, 118.80, 120.33, 122.03, 128.81, 129.26, 132.99, 137.13, 139.92, 140.81, 148.57, 149.01, 151.89, 155.74.

ESI-MS (m/z): theoretical 395.20 [C₂₂H₂₆N₄O₃+H]⁺, experimental 395.52 [C₂₂H₂₆N₄O₃+H]⁺.

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(3',4'-dimethoxy-[1,1'-biphenyl]-4-yl)urea **10d**




Following general procedure E compound **10d** was obtained starting from **5f**. **10d** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, R_f = 0.32). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (43 mg; yield 35%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.28 (s, 9H, (CH₃)₃), 3.77 (s, 3H, OCH₃), 3.83 (s, 3H, OCH₃), 6.38 (s, 1H, pyrazole), 7.18 – 7.12 (m, 2H, aromatic), 7.41 (tt, *J* = 5.2, 3.4 Hz, 1H, aromatic), 7.46 (d, *J* = 8.7 Hz, 2H, aromatic), 7.57 – 7.52 (m, 5H, aromatic), 8.30 (s, 1H, aromatic), 8.43 (s, 1H urea), 9.11 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 30.67, 32.52, 40.47, 56.00, 56.04, 79.62, 96.03, 110.42, 112.69, 118.68, 118.89, 124.77, 127.14, 127.75, 129.77, 133.10, 134.35, 137.66, 138.78, 139.03, 148.55, 149.50, 152.09, 161.28.

ESI-MS (m/z): theoretical 471.24 [C₂₈H₃₀N₄O₃+H]⁺, experimental 471.41 [C₂₈H₃₀N₄O₃+H]⁺.

1-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)-3-(3',4'-dimethoxy-[1,1'-biphenyl]-4-yl)urea **10e**




Following general procedure E compound **10e** was obtained starting from **5h**. **10e** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, $R_f = 0.55$). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (28 mg; yield 25%).

$^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ (ppm): 1.35 (d, $J = 6.6$ Hz, 6H, $(\text{CH}_3)_2\text{CH}$), 3.78 (s, 3H, OCH₃), 3.84 (s, 3H, OCH₃), 4.36 (hept, $J = 6.6$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 6.02 (s, 1H, pyrazole), 7.00 (d, $J = 8.4$ Hz, 1H, aromatic), 7.15 (dd, $J = 2.2, 8.3$ Hz, 1H, aromatic), 7.18 (d, $J = 2.2$ Hz, 1H, aromatic), 7.48 – 7.53 (m, 2H, aromatic), 7.55 – 7.59 (m, 2H, aromatic), 8.35 (s, 1H, urea), 8.93 (s, 1H, urea).

$^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ (ppm): 22.20, 30.45, 31.91, 47.67, 55.55 (d, $J = 7.1$ Hz), 94.42, 109.99, 112.23, 117.22, 118.19, 118.43, 120.59, 121.70, 124.60, 126.66, 130.72, 132.68, 133.76, 135.37, 138.49, 141.14, 148.07, 149.04, 152.17, 158.45.

ESI-MS (m/z): theoretical 437.25 [$\text{C}_{25}\text{H}_{32}\text{N}_4\text{O}_3$]⁺, experimental 437.45 [$\text{C}_{25}\text{H}_{32}\text{N}_4\text{O}_3$]⁺.

1-(1,3-diisopropyl-1H-pyrazol-5-yl)-3-(3',4'-dimethoxy-[1,1'-biphenyl]-4-yl)urea **10f**




Following general procedure E compound **10f** was obtained starting from **5x**. **10f** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, $R_f = 0.13$). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (51 mg; yield 46%).

$^1\text{H-NMR}$ (600 MHz, DMSO- d_6) δ (ppm): 1.17 (d, $J = 6.9$ Hz, 6H, $(\text{CH}_3)_2\text{CH}$), 1.34 (d, $J = 6.6$ Hz, 6H, $(\text{CH}_3)_2\text{CHN}$), 2.81 (hept, $J = 6.9$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 3.78 (s, 3H, OCH₃), 3.84 (s, 3H, OCH₃), 4.36 (hept, $J = 6.7$ Hz, 1H, $\text{NCH}(\text{CH}_3)_2$), 5.99 (s, 1H, pyrazole), 7.00 (d, $J = 8.4$ Hz, 1H, aromatic), 7.15 (dd, $J = 2.2, 8.3$ Hz, 1H, aromatic), 7.18 (d, $J = 2.2$ Hz, 1H, aromatic), 7.46 – 7.52 (m, 2H, aromatic), 7.55 – 7.59 (m, 2H, aromatic), 8.39 (s, 1H, urea), 8.92 (s, 1H, urea).

$^{13}\text{C-NMR}$ (151 MHz, DMSO- d_6) δ (ppm): 22.22, 22.76, 27.72, 40.06, 47.60, 54.91, 55.55 (d, $J = 7.2$ Hz), 94.63, 109.99, 112.23, 118.19, 118.45, 126.66, 132.68, 133.78, 135.54, 138.47, 148.07, 149.04, 152.13, 155.82.

ESI-MS (m/z): theoretical 423.24 [$\text{C}_{24}\text{H}_{30}\text{N}_4\text{O}_3+\text{H}$]⁺, experimental 423.51 [$\text{C}_{24}\text{H}_{30}\text{N}_4\text{O}_3+\text{H}$]⁺.

1-(3',4'-dimethoxy-[1,1'-biphenyl]-4-yl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea **10g**




Following general procedure D compound **10g** was obtained starting from **5k**. **10g** was purified by column chromatography using (Silica, DCM:EtOAc 98:2 → 9:1, R_f = 0.14). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (15 mg; yield 13%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.23 (d, *J* = 7.0 Hz, 6H, (CH₃)₂CH), 2.89 (hept, *J* = 6.9 Hz, 1H, CH(CH₃)₂), 3.76 (s, 3H, OCH₃), 3.82 (s, 3H, OCH₃), 6.34 (s, 1H, pyrazole), 6.99 (d, *J* = 8.4 Hz, 1H, aromatic), 7.10 – 7.20 (m, 2H, aromatic), 7.36 – 7.47 (m, 3H, aromatic), 7.48 – 7.60 (m, 6H), 8.41 (s, 1H, urea), 9.07 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 14.54, 22.92, 28.11, 56.01 (d, *J* = 6.4 Hz), 60.28, 96.41, 110.39, 112.68, 118.70, 118.96, 124.76, 127.14, 127.84, 129.80, 133.07, 134.40, 137.74, 138.69, 138.91, 148.54, 149.48, 152.07, 158.61.

ESI-MS (m/z): theoretical 457.22 [C₂₇H₂₈N₄O₃+H]⁺, experimental 457.58 [C₂₇H₂₈N₄O₃+H]⁺.

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(4'-methoxy-[1,1'-biphenyl]-4-yl)urea **10h**




Following general procedure E compound **10h** was obtained starting from **5f**. **10h** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, R_f = 0.37). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (49 mg; yield 43%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.29 (s, 9H, CH₃), 3.78 (s, 3H, OCH₃), 6.39 (s, 1H, pyrazole), 6.97 – 7.01 (m, 2H, aromatic), 7.41 (p, *J* = 4.3 Hz, 1H, aromatic), 7.45 – 7.47 (m, 2H, aromatic), 7.51 – 7.57 (m, 8H, aromatic), 8.45 (s, 1H, aromatic), 9.11 (s, 1H, aromatic).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 30.20, 30.69, 32.04, 54.91, 55.13, 59.75, 95.52, 114.30, 118.09, 118.49, 124.08, 124.29, 126.46, 127.18, 127.24, 128.80, 129.22, 129.28, 132.22, 133.58, 138.27, 138.59, 151.61, 158.47, 160.77, 206.49.

ESI-MS (*m/z*): theoretical 441.22 [C₂₇H₂₈N₄O₂+H]⁺, experimental 441.56 [C₂₇H₂₈N₄O₂+H]⁺.

1-(3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-yl)-3-(4'-methoxy-[1,1'-biphenyl]-4-yl)urea **10i**




Following general procedure D compound **10i** was obtained starting from **5x**. **10i** was purified by column chromatography using (Silica, DCM:EtOAc 98:2 → 9:1, *R*_f = 0.45). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (52 mg; yield 49%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.22 (s, 9H, (CH₃)₃), 1.35 (d, *J* = 6.6 Hz, 6H, (CH₃)₂CH), 3.79 (s, 3H, OCH₃), 4.36 (hept, 1H, CH(CH₃)₂), 6.02 (s, 1H, pyrazole), 6.92 – 7.03 (m, 2H, aromatic), 7.44 – 7.60 (m, 6H, aromatic), 8.35 (s, 1H, urea), 8.91 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 14.10, 20.78, 21.95, 22.21, 30.46, 31.93, 47.70, 55.15, 59.77, 94.46, 114.32, 118.15, 118.56, 126.48, 127.20, 132.28, 133.52, 135.38, 138.43, 152.21, 158.48.

ESI-MS (*m/z*): theoretical 407.24 [C₂₄H₃₀N₄O₂+H]⁺, experimental 407.43 [C₂₄H₃₀N₄O₂+H]⁺.

1-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)-3-(4'-methoxy-[1,1'-biphenyl]-4-yl)urea **10j**




Following general procedure E compound **10j** was obtained starting from **5t**. **10j** was purified by column chromatography (Silica, DCM:EtOAc 9:1 → 1:1, $R_f = 0.19$). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (36 mg; yield 38%).

¹H-NMR (600 MHz, DMSO- d_6) δ (ppm): 1.17 (d, $J = 6.9$ Hz, 6H, $(\text{CH}_3)_2\text{CH}$), 2.79 (hept, $J = 6.9$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 3.61 (s, 3H, OCH_3), 3.79 (s, 3H, NCH_3), 6.02 (s, 1H, pyrazole), 6.91 – 7.09 (m, 2H, aromatic), 7.44 – 7.63 (m, 6H, aromatic), 8.52 (s, 1H, urea), 8.93 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO- d_6) δ (ppm): 23.12, 28.01, 35.36, 55.62, 94.58, 114.79, 118.65, 119.05, 122.51, 126.96, 127.67, 129.29, 132.73, 134.05, 137.64, 138.80, 139.95, 152.27, 156.20, 158.95.

ESI-MS (m/z): theoretical 365.19 $[\text{C}_{21}\text{H}_{24}\text{N}_4\text{O}_2 + \text{H}]^+$, experimental 365.45 $[\text{C}_{21}\text{H}_{24}\text{N}_4\text{O}_2 + \text{H}]^+$.

1-(1,3-diisopropyl-1H-pyrazol-5-yl)-3-(4'-methoxy-[1,1'-biphenyl]-4-yl)urea **10k**




Following general procedure E compound **10k** was obtained starting from **5x**. Removal of the volatiles in vacuo provided a residue, which was purified by column chromatography (Silica, DCM:EtOAc 9:1 → 6:4, $R_f = 0.09$). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (49 mg; yield 48%).

¹H-NMR (400 MHz, DMSO- d_6) δ (ppm): 1.17 (d, 6H, $(\text{CH}_3)_2\text{CH}$), 1.34 (d, 6H, $(\text{CH}_3)_2\text{CHN}$), 2.81 (hept, 1H, $\text{CH}(\text{CH}_3)_2$), 3.79 (s, 3H, OCH_3), 4.36 (hept, 1H, $\text{NCH}(\text{CH}_3)_2$), 5.99 (s, 1H, pyrazole), 7.00 (m, 2H, aromatic), 7.54 (m, 6H, aromatic), 8.36 (s, 1H, urea), 8.87 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO- d_6) δ (ppm): 13C NMR (151 MHz, DMSO) δ 22.70, 23.24, 28.19, 48.09, 55.61, 95.14, 114.78, 119.05, 126.93, 127.66, 132.74, 133.96, 136.08, 138.91, 152.71, 156.34, 158.93.

ESI-MS (m/z): theoretical 393.22 $[\text{C}_{23}\text{H}_{28}\text{N}_4\text{O}_2 + \text{H}]^+$, experimental 393.50 $[\text{C}_{23}\text{H}_{28}\text{N}_4\text{O}_2 + \text{H}]^+$.

1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2'-methoxy-[1,1'-biphenyl]-4-yl)urea **10l**




Following general procedure E compound **10l** was obtained starting from **5f**. **10l** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 92:8, R_f = 0.37). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (70 mg; yield 61%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.29 (s, 9H, (CH₃)₃), 3.75 (s, 3H, OCH₃), 6.39 (s, 1H, pyrazole), 7.00 (td, *J* = 1.1, 7.4 Hz, 1H, aromatic), 7.08 (dd, *J* = 1.1, 8.3 Hz, 1H, aromatic), 7.26 (dd, *J* = 1.8, 7.5 Hz, 1H, aromatic), 7.30 (ddd, *J* = 1.8, 7.3, 8.3 Hz, 1H, aromatic), 7.36 – 7.40 (m, 2H, aromatic), 7.40 – 7.45 (m, 3H, aromatic), 7.53 – 7.55 (m, 4H, aromatic), 8.42 (s, 1H, urea), 9.07 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 14.08, 20.76, 30.20, 32.04, 55.45, 59.75, 95.49, 111.71, 117.72, 120.75, 124.31, 127.26, 128.42, 129.29, 129.45, 129.63, 130.10, 131.88, 137.22, 138.20, 138.59, 151.62, 156.10, 160.77, 170.33.

ESI-MS (m/z): theoretical 441.22 [C₂₇H₂₈N₄O₂+H]⁺, experimental 441.59 [C₂₇H₂₈N₄O₂+H]⁺.

1-(3-(tert-butyl)-1-methylisopropyl-1H-pyrazol-5-yl)-3-(2'-methoxy-[1,1'-biphenyl]-4-yl)urea **10m**




Following general procedure E compound **10m** was obtained starting from **5h**. **10m** was purified by column chromatography (Silica, DCM:EtOAc 9:1 → 1:1, R_f = 0.45). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (34 mg; yield 34%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.23 (s, 9H, (CH₃)₃), 3.36 (s, 3H, OCH₃), 6.06 (s, 1H, pyrazole), 7.36 – 7.24 (m, 42H), 7.51 – 7.36 (m, 2H), 7.55 (dd, *J* = 7.2, 1.9 Hz, 4H), 8.36 (s, 1H, urea), 8.99 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 21.94, 22.19, 30.19, 30.43, 30.45, 30.51, 55.21, 55.45, 110.29, 111.72, 113.34, 120.10, 120.25, 120.76, 131.51, 131.57, 131.77, 135.14, 135.30, 135.39, 138.37, 139.56, 152.21, 156.11, 158.44, 163.43

ESI-MS (m/z): theoretical 401.53 [C₂₄H₃₀N₄O₂+H]⁺, experimental 401.21 [C₂₄H₃₀N₄O₂+H]⁺.

1-(3-(tert-butyl)-1-methyl-1H-pyrazol-5-yl)-3-(2'-methoxy-[1,1'-biphenyl]-4-yl)urea **10n**




Following general procedure E compound **10n** was obtained starting from **5u**. **10n** was purified by column chromatography (Silica, DCM:EtOAc 9:1 → 1:1, R_f = 0.45). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (47 mg; yield 48%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.22 (s, 9H, (CH₃)₃), 3.61 (s, 3H, OCH₃), 3.76 (s, 3H, OCH₃), 6.06 (s, 1H, pyrazole), 7.01 (td, *J* = 7.4, 1.1 Hz, 1H, aromatic), 7.09 (dd, *J* = 8.3, 1.1 Hz, 1H, aromatic), 7.33 – 7.25 (m, 2H, aromatic), 7.40 (d, *J* = 8.6 Hz, 2H, aromatic), 7.48 (d, *J* = 8.7 Hz, 2H, aromatic), 8.53 (s, 1H, urea), 8.95 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 30.38, 31.81, 34.95, 55.46, 60.58, 65.86, 77.01, 93.53, 111.72, 117.76, 120.76, 128.41, 128.80, 129.49, 129.63, 130.11, 131.82, 137.11, 138.31, 151.82, 156.11, 158.52.

ESI-MS (m/z): theoretical 379.21 [C₂₂H₂₆N₄O₂+H]⁺, experimental 379.06 [C₂₂H₂₆N₄O₂+H]⁺.

1-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)-3-(2'-methoxy-[1,1'-biphenyl]-4-yl)urea **10o**




Following general procedure E compound **10o** was obtained starting from **5t**. **10o** was purified by column chromatography (Silica, DCM:EtOAc 9:1 → 1:1, R_f = 0.20). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (50 mg; yield 53%).

¹H-NMR (400 MHz, DMSO-*d*₆) δ (ppm): 1.18 (d, *J* = 6.6 Hz, 6H, (CH₃)₂CH), 2.78 (hept, *J* = 6.9 Hz, 1H, CH(CH₃)₂), 3.60 (s, 3H, COCH₃), 3.76 (s, 3H, NCH₃), 6.02 (s, 1H, pyrazole), 7.01 (td, *J* = 1.1, 7.4 Hz, 1H, aromatic), 7.09 (dd, *J* = 1.2, 8.2 Hz, 1H, aromatic), 7.24 – 7.35 (m, 2H, aromatic), 7.33 – 7.57 (m, 4H, aromatic), 8.53 (s, 1H, urea), 8.92 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 22.81, 27.69, 35.02, 55.64, 94.40, 111.91, 113.67, 118.10, 121.00, 128.68, 129.62, 129.84, 129.92, 129.98, 130.31, 132.14, 137.38, 138.37, 152.09, 156.09, 156.29.

ESI-MS (*m/z*): theoretical 365.19 [C₂₁H₂₄N₄O₂+H]⁺, experimental 365.41 [C₂₁H₂₄N₄O₂+H]⁺.

1-(3'-acetyl-[1,1'-biphenyl]-4-yl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea **10p**




Following general procedure E compound **10p** was obtained starting from **5f**. **10p** was purified by column chromatography (Silica, DCM:EtOAc 98:2 → 9:1, *R*_f = 0.64). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (42 mg; yield 36%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.29 (s, 9H, (CH₃)₃), 2.65 (s, 3H, COCH₃), 6.40 (s, 1H, pyrazole), 7.52 – 7.55 (m, 5H, aromatic), 7.57 – 7.60 (m, 1H, aromatic), 7.63 – 7.68 (m, 2H, aromatic), 7.90 (ddq, *J* = 1.1, 2.2, 7.9 Hz, 2H, aromatic), 8.15 (t, *J* = 1.8 Hz, 1H, aromatic), 8.31 (s, 2H, aromatic), 8.46 (s, 1H, urea), 9.20 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 14.10, 20.78, 26.94, 30.22, 32.07, 54.92, 59.78, 79.18, 95.64, 118.52, 124.32, 125.73, 126.56, 127.28, 129.32, 129.36, 130.77, 132.83, 137.14, 137.49, 138.59, 139.41, 140.19, 151.62, 160.82, 170.38, 198.12.

ESI-MS (*m/z*): theoretical 453.22 [C₂₈H₂₈N₄O₂+H]⁺, experimental 453.36 [C₂₈H₂₈N₄O₂+H]⁺.

1-(3'-acetyl-[1,1'-biphenyl]-4-yl)-3-(3-(tert-butyl)-1-methyl-1H-pyrazol-5-yl)urea **10q**




Following general procedure E compound **10q** was obtained starting from **5u**. **10q** was purified by column chromatography (Silica, DCM:EtOAc 9:1 → 1:1, R_f = 0.28). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (64 mg; 63%).

¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.22 (s, 9H, (CH₃)₃), 2.65 (s, 3H, COCH₃), 3.61 (s, 3H, NCH₃), 6.07 (s, 1H, pyrazole), 7.59 (t, *J* = 7.9 Hz, 3H, aromatic), 7.65 – 7.71 (m, 2H, aromatic), 7.90 (ddt, *J* = 1.3, 6.2, 7.7 Hz, 2H, aromatic), 8.16 (t, *J* = 1.8 Hz, 1H, aromatic), 8.54 (s, 1H, urea), 9.06 (s, 1H, urea).

¹³C-NMR (151 MHz, DMSO-*d*₆) δ (ppm): 26.93, 30.39, 34.95, 93.76, 118.56, 125.74, 126.53, 127.28, 129.34, 130.77, 132.78, 136.99, 137.48, 139.50, 140.21, 151.81, 158.55, 198.09.

ESI-MS (*m/z*): theoretical 391.21 [C₂₃H₂₆N₄O₂+H]⁺, experimental 391.50 [C₂₃H₂₆N₄O₂+H]⁺.

1-(3'-acetyl-[1,1'-biphenyl]-4-yl)-3-(3-isopropyl-1-phenyl-1H-pyrazol-5-yl)urea **10r**



Following general procedure E compound **10r** was obtained starting from **5k**. **10r** was purified by column chromatography using (Silica, DCM:EtOAc 98:2 → 9:1, R_f = 0.39). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (41 mg; yield 36%).


¹H-NMR (600 MHz, DMSO-*d*₆) δ (ppm): 1.24 (d, *J* = 6.9 Hz, 6H, (CH₃)₂CH), 2.65 (s, 3H, COCH₃), 2.90 (3.58 (s, 3H, NCH₃), *J* = 6.9 Hz, 1H, CH(CH₃)₂), 6.36 (s, 1H, pyrazole), 7.42 (p, *J* = 4.3 Hz, 1H, aromatic), 7.52 – 7.56 (m, 6H), 7.59 (t, *J* = 7.8 Hz, 1H, aromatic), 7.67 (d, *J* = 8.7 Hz, 2H, aromatic),

7.90 (ddd, $J = 0.9, 2.0, 7.1$ Hz, 2H, aromatic), 8.15 (t, $J = 1.9$ Hz, 1H, aromatic), 8.47 (s, 1H, urea), 9.18 (s, 1H, urea).

$^{13}\text{C-NMR}$ (151 MHz, $\text{DMSO-}d_6$) δ (ppm): 22.44, 26.91, 27.65, 95.93, 118.50, 124.30, 125.72, 126.53, 127.26, 127.30, 129.30, 129.32, 130.74, 132.82, 137.23, 137.47, 138.51, 139.37, 140.16, 151.55, 158.04, 198.06.

ESI-MS (m/z): theoretical 438.21 $[\text{C}_{27}\text{H}_{26}\text{N}_4\text{O}_2]^+$, experimental 437.28 $[\text{C}_{27}\text{H}_{26}\text{N}_4\text{O}_2]^+$.

1-(3'-acetyl-[1,1'-biphenyl]-4-yl)-3-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)urea **10s**





Following general procedure E compound **10s** was obtained starting from **5t**. **10s** was purified by column chromatography (Silica, DCM:EtOAc 9:1 → 1:1, $R_f = 0.14$ [as eluent 9:1]). Concentration in vacuo of the product-rich fractions gave the title product as a white powder (85 mg; yield 87%).



$^1\text{H-NMR}$ (600 MHz, $\text{DMSO-}d_6$) δ (ppm): 1.17 (d, $J = 6.9$ Hz, 6H, $(\text{CH}_3)_2\text{CH}$), 2.65 (s, 3H, CH_3), 2.78 (hept, $J = 6.9$ Hz, 1H, $\text{CH}(\text{CH}_3)_2$), 3.61 (s, 3H, NCH_3), 6.02 (s, 1H, pyrazole), 7.53 – 7.63 (m, 3H, aromatic), 7.65 – 7.71 (m, 2H, aromatic), 7.80 – 7.95 (m, 2H, aromatic), 8.16 (t, $J = 1.7$ Hz, 1H, aromatic), 8.68 (s, 1H, urea), 9.15 (s, 1H, urea).

$^{13}\text{C-NMR}$ (151 MHz, $\text{DMSO-}d_6$) δ (ppm): 22.65, 26.93, 27.54, 34.91, 94.16, 118.55, 125.74, 126.51, 127.26, 129.33, 130.76, 132.74, 137.15, 137.48, 139.54, 140.22, 151.83, 155.74, 198.09.



ESI-MS (m/z): theoretical 377.19 $[\text{C}_{22}\text{H}_{24}\text{N}_4\text{O}_2+\text{H}]^+$, experimental 377.42 $[\text{C}_{22}\text{H}_{24}\text{N}_4\text{O}_2+\text{H}]^+$.



9a








9b








9c









9d









9e








9f








9g














9i








10a




10b





10b







10c






10d








10e





- 158.46
- 152.18
- 149.05
- 148.08
- 138.50
- 135.38
- 133.77
- 132.69
- 126.67
- 118.44
- 118.20
- 112.24
- 110.00
- 94.43
- 55.59
- 55.54
- 47.68
- 31.92
- 30.46
- 22.21









































10q

